Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.01
FPMI's Cash to Debt is ranked lower than
100% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. FPMI: 0.01 )
Ranked among companies with meaningful Cash to Debt only.
FPMI' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: N/A Max: No Debt
Current: 0.01
F-Score: 3
Z-Score: -171.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROA (%) -354.10
FPMI's ROA (%) is ranked lower than
97% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. FPMI: -354.10 )
Ranked among companies with meaningful ROA (%) only.
FPMI' s ROA (%) Range Over the Past 10 Years
Min: -1659.13  Med: -301.97 Max: -100
Current: -354.1
-1659.13
-100
ROC (Joel Greenblatt) (%) -17902.17
FPMI's ROC (Joel Greenblatt) (%) is ranked lower than
92% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. FPMI: -17902.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FPMI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -19913.04  Med: -3147 Max: -186.67
Current: -17902.17
-19913.04
-186.67
EBITDA Growth (3Y)(%) -24.70
FPMI's EBITDA Growth (3Y)(%) is ranked lower than
77% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. FPMI: -24.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
FPMI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.7  Med: 81.45 Max: 460.4
Current: -24.7
-24.7
460.4
EPS Growth (3Y)(%) -12.60
FPMI's EPS Growth (3Y)(%) is ranked lower than
59% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. FPMI: -12.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
FPMI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -12.6 Max: 100
Current: -12.6
0
100
» FPMI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with FPMI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:ENUM, OTCPK:CDXI, OTCPK:PVOTF, AMEX:APHB, OTCPK:VRTHF, OTCPK:SGBI, NAS:GNVC, OTCPK:BPSR, NAS:BLPH, NAS:LPTN, NAS:OPXA, OTCPK:PPCH, OTCPK:BTHE, AMEX:BPMX, OTCPK:CBBT, OTCPK:CTBO, OTCPK:ISCO, OTCPK:HDVY, OTCPK:NMUS, OTCPK:TIKRF » details
FluoroPharma Medical Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization molecular imaging pharmaceuticals with initial applications in the area of cardiology.

FluoroPharma Medical Inc., is a molecular imaging company. It is engaged in the discovery, development and commercialization of proprietary products for the positron emission tomography (PET) market.

Ratios

vs
industry
vs
history
EV-to-EBIT -6.04
FPMI's EV-to-EBIT is ranked lower than
99.99% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. FPMI: -6.04 )
Ranked among companies with meaningful EV-to-EBIT only.
FPMI' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.97  Med: 0 Max: 0
Current: -6.04
-8.97
0
EV-to-EBITDA -6.20
FPMI's EV-to-EBITDA is ranked lower than
99.99% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. FPMI: -6.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
FPMI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.31  Med: 0 Max: 0
Current: -6.2
-9.31
0
Current Ratio 0.01
FPMI's Current Ratio is ranked lower than
100% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. FPMI: 0.01 )
Ranked among companies with meaningful Current Ratio only.
FPMI' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.19 Max: 21.99
Current: 0.01
0.01
21.99
Quick Ratio 0.01
FPMI's Quick Ratio is ranked lower than
100% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. FPMI: 0.01 )
Ranked among companies with meaningful Quick Ratio only.
FPMI' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.19 Max: 21.99
Current: 0.01
0.01
21.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.60
FPMI's 3-Year Average Share Buyback Ratio is ranked higher than
52% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. FPMI: -10.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FPMI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -32.7  Med: -18.6 Max: -1.4
Current: -10.6
-32.7
-1.4

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -16.53
FPMI's Earnings Yield (Greenblatt) (%) is ranked lower than
65% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. FPMI: -16.53 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FPMI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -46.4  Med: 0 Max: 0
Current: -16.53
-46.4
0

More Statistics

EPS (TTM) $ -0.12
Beta0.72
Short Percentage of Float0.00%
52-Week Range $0.10 - 0.37
Shares Outstanding (Mil)34.07
» More Articles for FPMI

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Dec 05 2016
FLUOROPHARMA MEDICAL, INC. Financials Nov 22 2016
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Nov 04 2016
FluoroPharma and Philips Collaborate on Image Management for CardioPET Phase II Clinical Trial Oct 18 2016
FluoroPharma and Philips Collaborate on Image Management for CardioPET Phase II Clinical Trial Oct 18 2016
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Sep 30 2016
FluoroPharma Announces CardioPET Phase II Results at the 21st American Society of Nuclear Cardiology... Sep 26 2016
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 18 2016
FLUOROPHARMA MEDICAL, INC. Files SEC form 10-Q, Quarterly Report Aug 15 2016
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jul 27 2016
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jul 18 2016
FluoroPharma Medical Announces Details for Investor Call on June 22, 2016 Jun 17 2016
FluoroPharma Medical Announces Details for Investor Call on June 22, 2016 Jun 17 2016
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jun 09 2016
FluoroPharma Announces a Letter of Intent to Acquire Ground Fluor Pharmaceuticals Jun 09 2016
FluoroPharma Announces a Letter of Intent to Acquire Ground Fluor Pharmaceuticals Jun 09 2016
FluoroPharma Enters Development and Commercialization Agreement for China and Canada Jun 06 2016
FluoroPharma Enters Development and Commercialization Agreement for China and Canada Jun 06 2016
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... May 31 2016
FluoroPharma Medical Announces Acceptance of CardioPET Data for Presentation at the 21st Scientific... May 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)